148 related articles for article (PubMed ID: 30498011)
1. MAGEA1 inhibits the expression of BORIS via increased promoter methylation.
Zhao J; Wang Y; Liang Q; Xu Y; Sang J
J Cell Sci; 2019 Jan; 132(1):. PubMed ID: 30498011
[TBL] [Abstract][Full Text] [Related]
2. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.
Woloszynska-Read A; James SR; Link PA; Yu J; Odunsi K; Karpf AR
Cancer Immun; 2007 Dec; 7():21. PubMed ID: 18095639
[TBL] [Abstract][Full Text] [Related]
3. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
[TBL] [Abstract][Full Text] [Related]
4. MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.
Zhao J; Wang Y; Mu C; Xu Y; Sang J
Oncogene; 2017 Aug; 36(35):5023-5034. PubMed ID: 28459460
[TBL] [Abstract][Full Text] [Related]
5. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
[TBL] [Abstract][Full Text] [Related]
6. Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.
Vatolin S; Abdullaev Z; Pack SD; Flanagan PT; Custer M; Loukinov DI; Pugacheva E; Hong JA; Morse H; Schrump DS; Risinger JI; Barrett JC; Lobanenkov VV
Cancer Res; 2005 Sep; 65(17):7751-62. PubMed ID: 16140943
[TBL] [Abstract][Full Text] [Related]
7. Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.
Hong JA; Kang Y; Abdullaev Z; Flanagan PT; Pack SD; Fischette MR; Adnani MT; Loukinov DI; Vatolin S; Risinger JI; Custer M; Chen GA; Zhao M; Nguyen DM; Barrett JC; Lobanenkov VV; Schrump DS
Cancer Res; 2005 Sep; 65(17):7763-74. PubMed ID: 16140944
[TBL] [Abstract][Full Text] [Related]
8. Differential regulation of MAGE-A1 promoter activity by BORIS and Sp1, both interacting with the TATA binding protein.
Schwarzenbach H; Eichelser C; Steinbach B; Tadewaldt J; Pantel K; Lobanenkov V; Loukinov D
BMC Cancer; 2014 Nov; 14():796. PubMed ID: 25363021
[TBL] [Abstract][Full Text] [Related]
9.
Hillman JC; Pugacheva EM; Barger CJ; Sribenja S; Rosario S; Albahrani M; Truskinovsky AM; Stablewski A; Liu S; Loukinov DI; Zentner GE; Lobanenkov VV; Karpf AR; Higgins MJ
Mol Cancer Res; 2019 Oct; 17(10):2051-2062. PubMed ID: 31292201
[TBL] [Abstract][Full Text] [Related]
10. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
Link PA; Zhang W; Odunsi K; Karpf AR
Cancer Immun; 2013; 13():6. PubMed ID: 23390377
[TBL] [Abstract][Full Text] [Related]
11. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Hoivik EA; Kusonmano K; Halle MK; Berg A; Wik E; Werner HM; Petersen K; Oyan AM; Kalland KH; Krakstad C; Trovik J; Widschwendter M; Salvesen HB
Oncotarget; 2014 Feb; 5(4):1052-61. PubMed ID: 24658009
[TBL] [Abstract][Full Text] [Related]
12. High expression of hTERT and stemness genes in BORIS/CTCFL positive cells isolated from embryonic cancer cells.
Alberti L; Renaud S; Losi L; Leyvraz S; Benhattar J
PLoS One; 2014; 9(10):e109921. PubMed ID: 25279549
[TBL] [Abstract][Full Text] [Related]
13. [BORIS Regulates SOCS3 Expression Through Epigenetic Mechanisms in Human Hepatocellular Carcinoma Cells].
He JY; Liu QY; Wei L; Liu ZJ; Huang Y; Yu XQ; Li B; Qin Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2018 Jan; 49(1):1-7. PubMed ID: 29737080
[TBL] [Abstract][Full Text] [Related]
14. Expression of the CTCF-paralogous cancer-testis gene, brother of the regulator of imprinted sites (BORIS), is regulated by three alternative promoters modulated by CpG methylation and by CTCF and p53 transcription factors.
Renaud S; Pugacheva EM; Delgado MD; Braunschweig R; Abdullaev Z; Loukinov D; Benhattar J; Lobanenkov V
Nucleic Acids Res; 2007; 35(21):7372-88. PubMed ID: 17962299
[TBL] [Abstract][Full Text] [Related]
15. BORIS (CTCFL) is not expressed in most human breast cell lines and high grade breast carcinomas.
Hines WC; Bazarov AV; Mukhopadhyay R; Yaswen P
PLoS One; 2010 Mar; 5(3):e9738. PubMed ID: 20305816
[TBL] [Abstract][Full Text] [Related]
16. Discovering a binary CTCF code with a little help from BORIS.
Lobanenkov VV; Zentner GE
Nucleus; 2018 Jan; 9(1):33-41. PubMed ID: 29077515
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic hierarchy within the MAGEA1 cancer-germline gene: promoter DNA methylation dictates local histone modifications.
Cannuyer J; Loriot A; Parvizi GK; De Smet C
PLoS One; 2013; 8(3):e58743. PubMed ID: 23472218
[TBL] [Abstract][Full Text] [Related]
18. The combined action of CTCF and its testis-specific paralog BORIS is essential for spermatogenesis.
Rivero-Hinojosa S; Pugacheva EM; Kang S; Méndez-Catalá CF; Kovalchuk AL; Strunnikov AV; Loukinov D; Lee JT; Lobanenkov VV
Nat Commun; 2021 Jun; 12(1):3846. PubMed ID: 34158481
[TBL] [Abstract][Full Text] [Related]
19. Targeting CTCFL/BORIS for the immunotherapy of cancer.
Loukinov D
Cancer Immunol Immunother; 2018 Dec; 67(12):1955-1965. PubMed ID: 30390146
[TBL] [Abstract][Full Text] [Related]
20. BORIS up-regulates OCT4 via histone methylation to promote cancer stem cell-like properties in human liver cancer cells.
Liu Q; Chen K; Liu Z; Huang Y; Zhao R; Wei L; Yu X; He J; Liu J; Qi J; Qin Y; Li B
Cancer Lett; 2017 Sep; 403():165-174. PubMed ID: 28645561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]